[ad_1]
Barenholz Y. Doxil®–the primary FDA-approved nano-drug: classes discovered. J Management Launch. 2012;160:117–34.
Prosperi D, Colombo M, Zanoni I, Granucci F. Drug nanocarriers to deal with autoimmunity and power inflammatory illnesses. Semin Immunol. 2017;34:61–7.
Wang H, Zhou Y, Solar Q, Zhou C, Hu S, Lenahan C, et al. Replace on nanoparticle-based drug supply system for anti-inflammatory therapy. Entrance Bioeng Biotechnol. 2021;9:630352.
Chen X, Zhuang Y, Rampal N, Hewitt R, Divitini G, O’Keefe CA, et al. Formulation of metal-organic framework-based drug carriers by managed coordination of methoxy PEG phosphate: boosting colloidal stability and redispersibility. J Am Chem Soc. 2021;143:13557–72.
Kinnear C, Moore TL, Rodriguez-Lorenzo L, Rothen-Rutishauser B, Petri-Fink A. Type follows perform: nanoparticle form and its implications for nanomedicine. Chem Rev. 2017;117:11476–521.
Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and challenges in the direction of focused supply of most cancers therapeutics. Nat Commun. 2018;9:1410.
Li Y, Liu C. Nanomaterial-based bone regeneration. Nanoscale. 2017;9:4862–74.
Jindal A, Sarkar S, Alam A. Nanomaterials-mediated immunomodulation for most cancers therapeutics. Entrance Chem. 2021;9:629635.
Parkin J, Cohen B. An outline of the immune system. Lancet. 2001;357:1777–89.
Hato T, Dagher PC. How the innate immune system senses hassle and causes hassle. Clin J Am Soc Nephrol. 2015;10:1459–69.
Netea MG, Schlitzer A, Placek Ok, Joosten LAB, Schultze JL. Innate and adaptive immune reminiscence: an evolutionary continuum within the host’s response to pathogens. Cell Host Microbe. 2019;25:13–26.
Farber DL, Netea MG, Radbruch A, Rajewsky Ok, Zinkernagel RM. Immunological reminiscence: classes from the previous and a glance to the long run. Nat Rev Immunol. 2016;16:124–8.
Bonilla FA, Oettgen HC. Adaptive immunity. J Allergy Clin Immunol. 2010;125:S33-40.
Eisenbarth SC, Baumjohann D, Craft J, Fazilleau N, Ma CS, Tangye SG, et al. CD4(+) T cells that assist B cells—a proposal for uniform nomenclature. Developments Immunol. 2021;42:658–69.
Dinarello CA. Anti-inflammatory brokers: current and future. Cell. 2010;140:935–50.
Wynn TA, Chawla A, Pollard JW. Macrophage biology in growth, homeostasis and illness. Nature. 2013;496:445–55.
Locati M, Curtale G, Mantovani A. Range, mechanisms, and significance of macrophage plasticity. Annu Rev Pathol. 2020;15:123–47.
Ginhoux F, Guilliams M. Tissue-resident macrophage ontogeny and homeostasis. Immunity. 2016;44:439–49.
Bajpai G, Schneider C, Wong N, Bredemeyer A, Hulsmans M, Nahrendorf M, et al. The human coronary heart incorporates distinct macrophage subsets with divergent origins and features. Nat Med. 2018;24:1234–45.
Funes SC, Rios M, Escobar-Vera J, Kalergis AM. Implications of macrophage polarization in autoimmunity. Immunology. 2018;154:186–95.
Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Esmaeili SA, Mardani F, et al. Macrophage plasticity, polarization, and performance in well being and illness. J Cell Physiol. 2018;233:6425–40.
Murray PJ. Macrophage polarization. Annu Rev Physiol. 2017;79:541–66.
Gaspar N, Zambito G, Löwik C, Mezzanotte L. Energetic nano-targeting of macrophages. Curr Pharm Des. 2019;25:1951–61.
Poupot R, Goursat C, Fruchon S. Multivalent nanosystems: focusing on monocytes/macrophages. Int J Nanomedicine. 2018;13:5511–21.
Heidt T, Sager HB, Courties G, Dutta P, Iwamoto Y, Zaltsman A, et al. Power variable stress prompts hematopoietic stem cells. Nat Med. 2014;20:754–8.
Mendelson A, Frenette PS. Hematopoietic stem cell area of interest upkeep throughout homeostasis and regeneration. Nat Med. 2014;20:833–46.
Shi C, Jia T, Mendez-Ferrer S, Hohl TM, Serbina NV, Lipuma L, et al. Bone marrow mesenchymal stem and progenitor cells induce monocyte emigration in response to circulating toll-like receptor ligands. Immunity. 2011;34:590–601.
Ozbakir B, Crielaard BJ, Metselaar JM, Storm G, Lammers T. Liposomal corticosteroids for the therapy of inflammatory problems and most cancers. J Management Launch. 2014;190:624–36.
Leuschner F, Dutta P, Gorbatov R, Novobrantseva TI, Donahoe JS, Courties G, et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol. 2011;29:1005–10.
Ordikhani F, Zandi N, Mazaheri M, Luther GA, Ghovvati M, Akbarzadeh A, et al. Focused nanomedicines for the therapy of bone illness and regeneration. Med Res Rev. 2021;41:1221–54.
Sou Ok, Goins B, Takeoka S, Tsuchida E, Phillips WT. Selective uptake of surface-modified phospholipid vesicles by bone marrow macrophages in vivo. Biomaterials. 2007;28:2655–66.
Agool A, Slart RH, Thorp KK, Glaudemans AW, Cobben DC, Been LB, et al. Impact of radiotherapy and chemotherapy on bone marrow exercise: a 18F-FLT-PET examine. Nucl Med Commun. 2011;32:17–22.
Ye YX, Calcagno C, Binderup T, Courties G, Keliher EJ, Wojtkiewicz GR, et al. Imaging macrophage and hematopoietic progenitor proliferation in atherosclerosis. Circ Res. 2015;117:835–45.
Alaarg A, Pérez-Medina C, Metselaar JM, Nahrendorf M, Fayad ZA, Storm G, et al. Making use of nanomedicine in maladaptive irritation and angiogenesis. Adv Drug Deliv Rev. 2017;119:143–58.
Qi D, Wei M, Jiao S, Music Y, Wang X, Xie G, et al. Hypoxia inducible issue 1α in vascular easy muscle cells promotes angiotensin II-induced vascular reworking through activation of CCL7-mediated macrophage recruitment. Cell Loss of life Dis. 2019;10:544.
Kratofil RM, Kubes P, Deniset JF. Monocyte conversion throughout irritation and damage. Arterioscler Thromb Vasc Biol. 2017;37:35–42.
Mack M. Irritation and fibrosis. Matrix Biol. 2018;68–69:106–21.
Wu Z, Chen C, Luo J, Davis JRJ, Zhang B, Tang L, et al. EGFP-EGF1-conjugated poly (lactic-co-glycolic acid) nanoparticles as a provider for the supply of CCR2- shRNA to atherosclerotic macrophage in vitro. Sci Rep. 2020;10:19636.
Krohn-Grimberghe M, Mitchell MJ, Schloss MJ, Khan OF, Courties G, Guimaraes PPG, et al. Nanoparticle-encapsulated siRNAs for gene silencing within the haematopoietic stem-cell area of interest. Nat Biomed Eng. 2020;4:1076–89.
Nakano Y, Matoba T, Tokutome M, Funamoto D, Katsuki S, Ikeda G, et al. Nanoparticle-mediated supply of irbesartan induces cardioprotection from myocardial ischemia-reperfusion damage by antagonizing monocyte-mediated irritation. Sci Rep. 2016;6:29601.
Ji H, Qiu R, Gao X, Zhang R, Li X, Hei Z, et al. Propofol attenuates monocyte-endothelial adhesion through modulating connexin43 expression in monocytes. Life Sci. 2019;232:116624.
Sager HB, Dutta P, Dahlman JE, Hulsmans M, Courties G, Solar Y, et al. RNAi focusing on a number of cell adhesion molecules reduces immune cell recruitment and vascular irritation after myocardial infarction. Sci Transl Med. 2016;8:342ra80.
Hesketh M, Sahin KB, West ZE, Murray RZ. Macrophage phenotypes regulate scar formation and power wound therapeutic. Int J Mol Sci. 2017. https://doi.org/10.3390/ijms18071545.
Galili U, Zhu Z, Chen J, Goldufsky JW, Schaer GL. Close to full restore after myocardial infarction in grownup mice by altering the inflammatory response with intramyocardial injection of α-gal nanoparticles. Entrance Cardiovasc Med. 2021;8:719160.
Kaymakcalan OE, Abadeer A, Goldufsky JW, Galili U, Karinja SJ, Dong X, et al. Topical α-gal nanoparticles speed up diabetic wound therapeutic. Exp Dermatol. 2020;29:404–13.
Galili U. Biosynthesis of α-Gal epitopes (Galα1-3Galβ1-4GlcNAc-R) and their distinctive potential in future α-Gal therapies. Entrance Mol Biosci. 2021;8:746883.
Jenkins SJ, Ruckerl D, Prepare dinner PC, Jones LH, Finkelman FD, van Rooijen N, et al. Native macrophage proliferation, slightly than recruitment from the blood, is a signature of TH2 irritation. Science. 2011;332:1284–8.
Hashimoto D, Chow A, Noizat C, Teo P, Beasley MB, Leboeuf M, et al. Tissue-resident macrophages self-maintain domestically all through grownup life with minimal contribution from circulating monocytes. Immunity. 2013;38:792–804.
Robbins CS, Hilgendorf I, Weber GF, Theurl I, Iwamoto Y, Figueiredo JL, et al. Native proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med. 2013;19:1166–72.
Lindau A, Härdtner C, Hergeth SP, Blanz KD, Dufner B, Hoppe N, et al. Atheroprotection by way of SYK inhibition fails in established illness when native macrophage proliferation dominates lesion development. Fundamental Res Cardiol. 2016;111:20.
McCloskey E, Paterson AH, Powles T, Kanis JA. Clodronate. Bone. 2021;143:115715.
Bacci M, Capobianco A, Monno A, Cottone L, Di Puppo F, Camisa B, et al. Macrophages are alternatively activated in sufferers with endometriosis and required for development and vascularization of lesions in a mouse mannequin of illness. Am J Pathol. 2009;175:547–56.
Zhang Q, Yuan R, Li C, Wei W, Shen W, Cui Y, et al. Macrophage depletion with clodronate-containing liposomes impacts the incidence and growth of rheumatoid arthritis. Z Rheumatol. 2019;78:996–1003.
Richards PJ, Williams AS, Goodfellow RM, Williams BD. Liposomal clodronate eliminates synovial macrophages, reduces irritation and ameliorates joint destruction in antigen-induced arthritis. Rheumatology. 1999;38:818–25.
Qi R, Majoros I, Misra AC, Koch AE, Campbell P, Marotte H, et al. Folate receptor-targeted dendrimer-methotrexate conjugate for inflammatory arthritis. J Biomed Nanotechnol. 2015;11:1431–41.
Thomas TP, Goonewardena SN, Majoros IJ, Kotlyar A, Cao Z, Leroueil PR, et al. Folate-targeted nanoparticles present efficacy within the therapy of inflammatory arthritis. Arthritis Rheum. 2011;63:2671–80.
Duivenvoorden R, Tang J, Cormode DP, Mieszawska AJ, Izquierdo-Garcia D, Ozcan C, et al. A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque irritation. Nat Commun. 2014;5:3065.
Tang J, Lobatto ME, Hassing L, van der Staay S, van Rijs SM, Calcagno C, et al. Inhibiting macrophage proliferation suppresses atherosclerotic plaque irritation. Sci Adv. 2015. https://doi.org/10.1126/sciadv.1400223.
Miao X, Leng X, Zhang Q. The present state of nanoparticle-induced macrophage polarization and reprogramming analysis. Int J Mol Sci. 2017. https://doi.org/10.3390/ijms18020336.
Ahamad N, Kar A, Mehta S, Dewani M, Ravichandran V, Bhardwaj P, et al. Immunomodulatory nanosystems for treating inflammatory illnesses. Biomaterials. 2021;274:120875.
Brown BN, Ratner BD, Goodman SB, Amar S, Badylak SF. Macrophage polarization: a possibility for improved outcomes in biomaterials and regenerative drugs. Biomaterials. 2012;33:3792–802.
Kwon D, Cha BG, Cho Y, Min J, Park EB, Kang SJ, et al. Additional-large pore mesoporous silica nanoparticles for guiding in vivo M2 macrophage polarization by delivering IL-4. Nano Lett. 2017;17:2747–56.
Taratummarat S, Sangphech N, Vu CTB, Palaga T, Ondee T, Surawut S, et al. Gold nanoparticles attenuates bacterial sepsis in cecal ligation and puncture mouse mannequin by way of the induction of M2 macrophage polarization. BMC Microbiol. 2018;18:85.
Tran TH, Rastogi R, Shelke J, Amiji MM. Modulation of macrophage practical polarity in the direction of anti-inflammatory phenotype with plasmid DNA supply in CD44 focusing on hyaluronic acid nanoparticles. Sci Rep. 2015;5:16632.
Tran TH, Krishnan S, Amiji MM. MicroRNA-223 induced repolarization of peritoneal macrophages utilizing CD44 focusing on hyaluronic acid nanoparticles for anti-inflammatory results. PLoS ONE. 2016;11:e0152024.
Han J, Kim YS, Lim MY, Kim HY, Kong S, Kang M, et al. Twin roles of graphene oxide to attenuate irritation and elicit well timed polarization of macrophage phenotypes for cardiac restore. ACS Nano. 2018;12:1959–77.
Parodi A, Quattrocchi N, van de Ven AL, Chiappini C, Evangelopoulos M, Martinez JO, et al. Artificial nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like features. Nat Nanotechnol. 2013;8:61–8.
Fang RH, Kroll AV, Gao W, Zhang L. Cell membrane coating nanotechnology. Adv Mater. 2018;30:e1706759.
Molinaro R, Corbo C, Martinez JO, Taraballi F, Evangelopoulos M, Minardi S, et al. Biomimetic proteolipid vesicles for focusing on infected tissues. Nat Mater. 2016;15:1037–46.
Polak R, Lim RM, Beppu MM, Pitombo RN, Cohen RE, Rubner MF. Liposome-loaded cell backpacks. Adv Healthc Mater. 2015;4:2832–41.
Anselmo AC, Mitragotri S. Cell-mediated supply of nanoparticles: benefiting from circulatory cells to focus on nanoparticles. J Management Launch. 2014;190:531–41.
Dou H, Grotepas CB, McMillan JM, Destache CJ, Chaubal M, Werling J, et al. Macrophage supply of nanoformulated antiretroviral drug to the mind in a murine mannequin of neuroAIDS. J Immunol. 2009;183:661–9.
Brynskikh AM, Zhao Y, Mosley RL, Li S, Boska MD, Klyachko NL, et al. Macrophage supply of therapeutic nanozymes in a murine mannequin of Parkinson’s illness. Nanomedicine. 2010;5:379–96.
Ahrens ET, Bulte JW. Monitoring immune cells in vivo utilizing magnetic resonance imaging. Nat Rev Immunol. 2013;13:755–63.
Richards JM, Shaw CA, Lang NN, Williams MC, Semple SI, MacGillivray TJ, et al. In vivo mononuclear cell monitoring utilizing superparamagnetic particles of iron oxide: feasibility and security in people. Circ Cardiovasc Imaging. 2012;5:509–17.
Bönner F, Merx MW, Klingel Ok, Begovatz P, Flögel U, Sager M, et al. Monocyte imaging after myocardial infarction with 19F MRI at 3 T: a pilot examine in explanted porcine hearts. Eur Coronary heart J Cardiovasc Imaging. 2015;16:612–20.
Thurlings RM, Wijbrandts CA, Bennink RJ, Dohmen SE, Voermans C, Wouters D, et al. Monocyte scintigraphy in rheumatoid arthritis: the dynamics of monocyte migration in immune-mediated inflammatory illness. PLoS ONE. 2009;4:e7865.
Kircher MF, Grimm J, Swirski FK, Libby P, Gerszten RE, Allport JR, et al. Noninvasive in vivo imaging of monocyte trafficking to atherosclerotic lesions. Circulation. 2008;117:388–95.
Thamphiwatana S, Angsantikul P, Escajadillo T, Zhang Q, Olson J, Luk BT, et al. Macrophage-like nanoparticles concurrently absorbing endotoxins and proinflammatory cytokines for sepsis administration. Proc Natl Acad Sci USA. 2017;114:11488–93.
Park J, Zhang Y, Saito E, Gurczynski SJ, Moore BB, Cummings BJ, et al. Intravascular innate immune cells reprogrammed through intravenous nanoparticles to advertise practical restoration after spinal wire damage. Proc Natl Acad Sci USA. 2019;116:14947–54.
Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils within the activation and regulation of innate and adaptive immunity. Nat Rev Immunol. 2011;11:519–31.
Liew PX, Kubes P. The neutrophil’s function throughout well being and illness. Physiol Rev. 2019;99:1223–48.
Borregaard N. Neutrophils, from marrow to microbes. Immunity. 2010;33:657–70.
Lawrence SM, Corriden R, Nizet V. The ontogeny of a neutrophil: mechanisms of granulopoiesis and homeostasis. Microbiol Mol Biol Rev. 2018. https://doi.org/10.1128/MMBR.00057-17.
Summers C, Rankin SM, Condliffe AM, Singh N, Peters AM, Chilvers ER. Neutrophil kinetics in well being and illness. Developments Immunol. 2010;31:318–24.
Kolaczkowska E, Kubes P. Neutrophil recruitment and performance in well being and irritation. Nat Rev Immunol. 2013;13:159–75.
Manfredi AA, Ramirez GA, Rovere-Querini P, Maugeri N. The neutrophil’s alternative: phagocytose vs make neutrophil extracellular traps. Entrance Immunol. 2018;9:288.
Fromen CA, Kelley WJ, Fish MB, Adili R, Noble J, Hoenerhoff MJ, et al. Neutrophil-particle interactions in blood circulation drive particle clearance and alter neutrophil responses in acute irritation. ACS Nano. 2017;11:10797–807.
Saito E, Kuo R, Pearson RM, Gohel N, Cheung B, King NJC, et al. Designing drug-free biodegradable nanoparticles to modulate inflammatory monocytes and neutrophils for ameliorating irritation. J Management Launch. 2019;300:185–96.
Zhang CY, Dong X, Gao J, Lin W, Liu Z, Wang Z. Nanoparticle-induced neutrophil apoptosis will increase survival in sepsis and alleviates neurological harm in stroke. Sci Adv. 2019;5:eaax7964.
Colón DF, Wanderley CW, Franchin M, Silva CM, Hiroki CH, Castanheira FVS, et al. Neutrophil extracellular traps (NETs) exacerbate severity of toddler sepsis. Crit Care. 2019;23:113.
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: take into account cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–4.
Lee YY, Park HH, Park W, Kim H, Jang JG, Hong KS, et al. Lengthy-acting nanoparticulate DNase-1 for efficient suppression of SARS-CoV-2-mediated neutrophil actions and cytokine storm. Biomaterials. 2021;267:120389.
Wang Z, Li J, Cho J, Malik AB. Prevention of vascular irritation by nanoparticle focusing on of adherent neutrophils. Nat Nanotechnol. 2014;9:204–10.
Chu D, Dong X, Shi X, Zhang C, Wang Z. Neutrophil-based drug supply methods. Adv Mater. 2018;30:e1706245.
Chu D, Gao J, Wang Z. Neutrophil-mediated supply of therapeutic nanoparticles throughout blood vessel barrier for therapy of irritation and an infection. ACS Nano. 2015;9:11800–11.
Zhang C, Ling CL, Pang L, Wang Q, Liu JX, Wang BS, et al. Direct macromolecular drug supply to cerebral ischemia space utilizing neutrophil-mediated nanoparticles. Theranostics. 2017;7:3260–75.
Zhang Q, Dehaini D, Zhang Y, Zhou J, Chen X, Zhang L, et al. Neutrophil membrane-coated nanoparticles inhibit synovial irritation and alleviate joint harm in inflammatory arthritis. Nat Nanotechnol. 2018;13:1182–90.
Liu Z, Liu X, Yang Q, Yu L, Chang Y, Qu M. Neutrophil membrane-enveloped nanoparticles for the amelioration of renal ischemia-reperfusion damage in mice. Acta Biomater. 2020;104:158–66.
Gao J, Chu D, Wang Z. Cell membrane-formed nanovesicles for disease-targeted supply. J Management Launch. 2016;224:208–16.
Gao J, Wang S, Wang Z. Excessive yield, scalable and remotely drug-loaded neutrophil-derived extracellular vesicles (EVs) for anti-inflammation remedy. Biomaterials. 2017;135:62–73.
Orkin SH, Zon LI. Hematopoiesis: an evolving paradigm for stem cell biology. Cell. 2008;132:631–44.
Brandstadter JD, Maillard I. Notch signalling in T cell homeostasis and differentiation. Open Biol. 2019;9:190187.
Zhao X, Shan Q, Xue HH. TCF1 in T cell immunity: a broadened frontier. Nat Rev Immunol. 2021. https://doi.org/10.1038/s41577-021-00563-6.
Natoli G, Ostuni R. Adaptation and reminiscence in immune responses. Nat Immunol. 2019;20:783–92.
Wang Y, Liu J, Burrows PD, Wang JY. B cell growth and maturation. Adv Exp Med Biol. 2020;1254:1–22.
Seifert M, Küppers R. Human reminiscence B cells. Leukemia. 2016;30:2283–92.
Smarr CB, Yap WT, Neef TP, Pearson RM, Hunter ZN, Ifergan I, et al. Biodegradable antigen-associated PLG nanoparticles tolerize Th2-mediated allergic airway irritation pre- and postsensitization. Proc Natl Acad Sci USA. 2016;113:5059–64.
Hunter Z, McCarthy DP, Yap WT, Harp CT, Getts DR, Shea LD, et al. A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for therapy of autoimmune illness. ACS Nano. 2014;8:2148–60.
Yeste A, Takenaka MC, Mascanfroni ID, Nadeau M, Kenison JE, Patel B, et al. Tolerogenic nanoparticles inhibit T cell-mediated autoimmunity by way of SOCS2. Sci Sign. 2016;9:ra61.
Clemente-Casares X, Blanco J, Ambalavanan P, Yamanouchi J, Singha S, Fandos C, et al. Increasing antigen-specific regulatory networks to deal with autoimmunity. Nature. 2016;530:434–40.
Singha S, Shao Ok, Yang Y, Clemente-Casares X, Solé P, Clemente A, et al. Peptide-MHC-based nanomedicines for autoimmunity perform as T-cell receptor microclustering gadgets. Nat Nanotechnol. 2017;12:701–10.
Heymann F, Tacke F. Immunology within the liver–from homeostasis to illness. Nat Rev Gastroenterol Hepatol. 2016;13:88–110.
Liu Q, Wang X, Liu X, Kumar S, Gochman G, Ji Y, et al. Use of polymeric nanoparticle platform focusing on the liver to induce Treg-mediated antigen-specific immune tolerance in a pulmonary allergen sensitization mannequin. ACS Nano. 2019;13:4778–94.
Kunnumakkara AB, Bordoloi D, Padmavathi G, Monisha J, Roy NK, Prasad S, et al. Curcumin, the golden nutraceutical: multitargeting for a number of power illnesses. Br J Pharmacol. 2017;174:1325–48.
Ohno M, Nishida A, Sugitani Y, Nishino Ok, Inatomi O, Sugimoto M, et al. Nanoparticle curcumin ameliorates experimental colitis through modulation of intestine microbiota and induction of regulatory T cells. PLoS ONE. 2017;12:e0185999.
Epstein J, Sanderson IR, Macdonald TT. Curcumin as a therapeutic agent: the proof from in vitro, animal and human research. Br J Nutr. 2010;103:1545–57.
Ong SY, de Mel S, Grigoropoulos NF, Chen Y, Tan YC, Tan MSY, et al. Excessive-dose methotrexate is efficient for prevention of remoted CNS relapse in diffuse giant B cell lymphoma. Blood Most cancers J. 2021;11:143.
Aletaha D, Westhovens R, Gaujoux-Viala C, Adami G, Matsumoto A, Chook P, et al. Efficacy and security of filgotinib in methotrexate-naive sufferers with rheumatoid arthritis with poor prognostic elements: submit hoc evaluation of FINCH 3. RMD Open. 2021. https://doi.org/10.1136/rmdopen-2021-001621.
Chan ES, Cronstein BN. Methotrexate—how does it actually work? Nat Rev Rheumatol. 2010;6:175–8.
Özcan A, Sahin D, Impellizzieri D, Nguyen TT, Hafner J, Yawalkar N, et al. Nanoparticle-coupled topical methotrexate can normalize immune responses and induce tissue reworking in psoriasis. J Make investments Dermatol. 2020;140:1003-14.e8.
Smelkinson MG. The hedgehog signaling pathway emerges as a pathogenic goal. J Dev Biol. 2017. https://doi.org/10.3390/jdb5040014.
Haycook CP, Balsamo JA, Glass EB, Williams CH, Hong CC, Main AS, et al. PEGylated PLGA nanoparticle supply of eggmanone for T cell modulation: purposes in rheumatic autoimmunity. Int J Nanomedicine. 2020;15:1215–28.
Peters MC, Ringel L, Dyjack N, Herrin R, Woodruff PG, Rios C, et al. A transcriptomic technique to find out airway immune dysfunction in T2-high and T2-low bronchial asthma. Am J Respir Crit Care Med. 2019;199:465–77.
Wu Y, Shi W, Wang H, Yue J, Mao Y, Zhou W, et al. Anti-ST2 nanoparticle alleviates lung irritation by focusing on ILC2s-CD4(+)T response. Int J Nanomedicine. 2020;15:9745–58.
Yang J, Reth M. Receptor dissociation and B-cell activation. Curr Prime Microbiol Immunol. 2016;393:27–43.
Derksen V, Huizinga TWJ, van der Woude D. The function of autoantibodies within the pathophysiology of rheumatoid arthritis. Semin Immunopathol. 2017;39:437–46.
Bednar KJ, Nycholat CM, Rao TS, Paulson JC, Fung-Leung WP, Macauley MS. Exploiting CD22 to selectively tolerize autoantibody producing B-cells in rheumatoid arthritis. ACS Chem Biol. 2019;14:644–54.
Pozsgay J, Babos F, Uray Ok, Magyar A, Gyulai G, Kiss É, et al. In vitro eradication of citrullinated protein particular B-lymphocytes of rheumatoid arthritis sufferers by focused bifunctional nanoparticles. Arthritis Res Ther. 2016;18:15.
Carnasciali A, Amoriello R, Bonechi E, Mazzoni A, Ravagli C, Doumett S, et al. T cell supply of nanoparticles-bound anti-CD20 monoclonal antibody: profitable B cell depletion within the spinal wire throughout experimental autoimmune encephalomyelitis. J Neuroimmune Pharmacol. 2021;16:376–89.
Zhong G, Yang X, Jiang X, Kumar A, Lengthy H, Xie J, et al. Dopamine-melanin nanoparticles scavenge reactive oxygen and nitrogen species and activate autophagy for osteoarthritis remedy. Nanoscale. 2019;11:11605–16.
Yang B, Chen Y, Shi J. Reactive oxygen species (ROS)-based nanomedicine. Chem Rev. 2019;119:4881–985.
Liu Y, Ai Ok, Ji X, Askhatova D, Du R, Lu L, et al. Complete insights into the multi-antioxidative mechanisms of melanin nanoparticles and their software to guard mind from damage in ischemic stroke. J Am Chem Soc. 2017;139:856–62.
Chen Z, Vong CT, Gao C, Chen S, Wu X, Wang S, et al. Bilirubin nanomedicines for the therapy of reactive oxygen species (ROS)-mediated illnesses. Mol Pharm. 2020;17:2260–74.
Lee Y, Kim H, Kang S, Lee J, Park J, Jon S. Bilirubin nanoparticles as a nanomedicine for anti-inflammation remedy. Angew Chem Int Ed Engl. 2016;55:7460–3.
Kim MJ, Lee Y, Jon S, Lee DY. PEGylated bilirubin nanoparticle as an anti-oxidative and anti inflammatory demulcent in pancreatic islet xenotransplantation. Biomaterials. 2017;133:242–52.
Aratani Y. Myeloperoxidase: its function for host protection, irritation, and neutrophil perform. Arch Biochem Biophys. 2018;640:47–52.
Sanfins E, Correia A, Stefan BG, Vilanova M, Cedervall T. Nanoparticle impact on neutrophil produced myeloperoxidase. PLoS ONE. 2018;13:e0191445.
Papayannopoulos V. Neutrophil extracellular traps in immunity and illness. Nat Rev Immunol. 2018;18:134–47.
Pereira A, Brito GAC, Lima MLS, Silva Júnior AAD, Silva EDS, de Rezende AA, et al. Metformin hydrochloride-loaded PLGA nanoparticle in periodontal illness experimental mannequin utilizing diabetic rats. Int J Mol Sci. 2018. https://doi.org/10.3390/ijms19113488.
Rodriguez-Nogales A, Lozano-Pérez AA, Aznar-Cervantes SD, Algieri F, Garrido-Mesa J, Garrido-Mesa N, et al. Impact of aqueous and particulate silk fibroin in a rat mannequin of experimental colitis. Int J Pharm. 2016;511:1–9.
Gou S, Huang Y, Sung J, Xiao B, Merlin D. Silk fibroin-based nanotherapeutics: software within the therapy of colonic illnesses. Nanomedicine. 2019;14:2373–8.
Boraschi D, Italiani P, Palomba R, Decuzzi P, Duschl A, Fadeel B, et al. Nanoparticles and innate immunity: new views on host defence. Semin Immunol. 2017;34:33–51.
Ricklin D, Hajishengallis G, Yang Ok, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11:785–97.
Waisman A, Lukas D, Clausen BE, Yogev N. Dendritic cells as gatekeepers of tolerance. Semin Immunopathol. 2017;39:153–63.
Gardner A, de Mingo PÁ, Ruffell B. Dendritic cells and their function in immunotherapy. Entrance Immunol. 2020;11:924.
Deng Z, Rong Y, Teng Y, Mu J, Zhuang X, Tseng M, et al. Broccoli-derived nanoparticle inhibits mouse colitis by activating dendritic cell AMP-activated protein kinase. Mol Ther. 2017;25:1641–54.
Gao J, Ochyl LJ, Yang E, Moon JJ. Cationic liposomes promote antigen cross-presentation in dendritic cells by alkalizing the lysosomal pH and limiting the degradation of antigens. Int J Nanomedicine. 2017;12:1251–64.
Mikelez-Alonso I, Magadán S, González-Fernández Á, Borrego F. Pure killer (NK) cell-based immunotherapies and the various faces of NK cell reminiscence: a glance into how nanoparticles improve NK cell exercise. Adv Drug Deliv Rev. 2021;176:113860.
Liao N, Su L, Zheng Y, Zhao B, Wu M, Zhang D, et al. In vivo monitoring of cell viability for adoptive pure killer cell-based immunotherapy by ratiometric NIR-II fluorescence imaging. Angew Chem Int Ed Engl. 2021;60:20888–96.
Zachs DP, Offutt SJ, Graham RS, Kim Y, Mueller J, Auger JL, et al. Noninvasive ultrasound stimulation of the spleen to deal with inflammatory arthritis. Nat Commun. 2019;10:951.
Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023–38.
Rendon A, Schakel Ok. Psoriasis pathogenesis and therapy. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20061475.
van der Valk FM, van Wijk DF, Lobatto ME, Verberne HJ, Storm G, Willems MC, et al. Prednisolone-containing liposomes accumulate in human atherosclerotic macrophages upon intravenous administration. Nanomedicine. 2015;11:1039–46.
Silva AL, Peres C, Conniot J, Matos AI, Moura L, Carreira B, et al. Nanoparticle impression on innate immune cell pattern-recognition receptors and inflammasomes activation. Semin Immunol. 2017;34:3–24.
Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug supply. Nat Rev Drug Discov. 2021;20:101–24.
Chen W, Schilperoort M, Cao Y, Shi J, Tabas I, Tao W. Macrophage-targeted nanomedicine for the analysis and therapy of atherosclerosis. Nat Rev Cardiol. 2021. https://doi.org/10.1038/s41569-021-00629-x.
Paik J, Duggan ST, Keam SJ. Triamcinolone acetonide extended-release: a evaluation in osteoarthritis ache of the knee. Medicine. 2019;79:455–62.
Anselmo AC, Mitragotri S. Nanoparticles within the clinic: an replace. Bioeng Transl Med. 2019;4:e10143.
Huang H, Feng W, Chen Y, Shi J. Inorganic nanoparticles in medical trials and translations. Nano Immediately. 2020;35:100972.
Guo Y, Solar Q, Wu FG, Dai Y, Chen X. Polyphenol-containing nanoparticles: synthesis, properties, and therapeutic supply. Adv Mater. 2021;33:e2007356.
[ad_2]
